Please assess the completion status of the following clinical trial:

Trial Title: A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (patients, as appropriate)~* Genetically-confirmed Prader-Willi syndrome and hyperphagic~* In a stable care setting for at least 6 months prior to Visit 1~* Caregiver must have been caring for the patient for at least 6 months prior to Visit 1~Exclusion Criteria:~* Have participated in an interventional clinical study (i.e., investigational drug or device, approved drugs or device evaluated for unapproved use) within prior 3 months~* Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation~* Any other known disease and/or condition, which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCCR (Type: EXPERIMENTAL): 75 - 450 mg DCCR
- Placebo (Type: PLACEBO_COMPARATOR): 75 - 450 mg placebo for DCCR

Based on this trial design, predict the completion outcome and termination type (if applicable).